Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
7.16
Nov 17 • 3:50 PM ET Dollar change-0.51 Percentage change(-6.65%)
Nov 16, 7:15 PMHelus Pharma reports fiscal Q2 2027 results with non-GAAP EPS $-1.16 (+14% YoY) and revenue $0, misses EPS but beats revenue estimates
Index
-
Market Cap
523.11M
Enterprise Value
353.00M
Income
-240.57M
Sales
0.00M
Book/sh
3.07
Cash/sh
2.34
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
100
IPO
Sep 13, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.33
P/C
3.06
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
10.90
Current Ratio
10.90
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-4.26
EPS next Y
-2.46
EPS next Q
-0.64
EPS this Y
27.43%
EPS next Y
20.36%
EPS next 5Y
23.42%
EPS past 3/5Y
16.70% 14.41%
Sales past 3/5Y
- -
EPS Y/Y TTM
-9.63%
Sales Y/Y TTM
-
EPS Q/Q
-1.28%
Sales Q/Q
-
Insider Own
28.57%
Insider Trans
3.92%
Inst Own
37.36%
Inst Trans
11.49%
ROA
-108.26%
ROE
-125.50%
ROIC
-98.07%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-24.16%
SMA50
-35.15%
SMA200
-8.15%
Trades
Shs Outstand
79.55M
Shs Float
52.18M
52W High
15.15 -52.74%
52W Low
3.76 90.43%
Volatility
13.01% 10.27%
ATR (14)
0.97
RSI (14)
29.09
Beta
0.69
Rel Volume
1.63
Avg Volume
1.75M
Volume
2,784,064
Perf Week
-21.06%
Perf Month
-33.02%
Perf Quarter
-39.22%
Perf Half Y
71.29%
Perf YTD
-12.47%
Perf Year
17.96%
Perf 3Y
-58.13%
Perf 5Y
-89.17%
Perf 10Y
-
Prev Close
7.67
Price
7.16
Change %
-6.65%
Consensus
Strong Buy
Avg. Price Target
$46.12
Implied Upside
+544.1%
Analysts5incl. previous ratings
Rating Distribution4 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 27, 2026Initiated
WFC logoWWells Fargo
Overweight$16+123.5%
Apr 13, 2026Initiated
TD logoTTD Cowen
Buy$8+11.7%
Feb 02, 2026Initiated
JEF logoJJefferies
Buy$22+207.3%
Mar 13, 2025Initiated
GGuggenheim
Buy$35+388.8%
Nov 19, 2021Downgrade
MMaxim Group
Buy → Hold
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cavers GregChief Financial OfficerSep 29 '26Buy12.913,00038,7303,000Oct 01 08:13 PM
Halstead MichaelChief Executive OfficerSep 21 '26Buy13.47100,0001,347,050168,568Sep 21 05:07 PM
Glavine PaulChief Growth OfficerSep 08 '26Buy12.47100,0001,247,1904,271,252Sep 11 09:04 AM
Glavine PaulChief Growth OfficerSep 08 '26Buy12.47100,0001,247,1904,271,252Sep 11 09:03 AM
So Eric H. L.Executive ChairSep 08 '26Buy12.39100,0001,238,6704,465,014Sep 11 09:01 AM
So Eric H. L.Executive ChairSep 04 '26Buy12.09100,0001,208,9004,365,014Sep 10 06:21 AM
Glavine PaulChief Growth OfficerSep 03 '26Buy11.78100,0001,178,2804,171,252Sep 10 06:19 AM
So Eric H. L.Executive ChairSep 01 '26Buy11.8095,0001,121,4754,265,014Sep 09 05:47 PM
Glavine PaulChief Growth OfficerAug 31 '26Buy11.5990,0001,042,6774,071,252Sep 09 11:03 AM
Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
Co-Founder & Chairman EmeritusMr. Eric So L.L.B.
Co-Founder & DirectorMr. Paul Glavine
Chief Financial OfficerMr. Greg Cavers
Chief Operating OfficerMr. Aaron Bartlone
MBBSDr. Amir Inamdar FFPM